首页> Advanced science (Weinheim, Baden-Wurttemberg, Germany)> Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer.

Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Huaiyuan,Liang

第一单位： Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.;Uro-Oncology Institute of Central South University, Changsha, Hunan, 410011, China.

作者： Huaiyuan,Liang ^[1] ; Chunguang,Yang ^[2] ; Ruijiang,Zeng ^[1] ; Yingqiu,Song ^[3] ; Jianxi,Wang ^[4] ; Wei,Xiong ^[1] ; Binyuan,Yan ^[5] ; Xin,Jin ^[1]

作者单位： Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.;Uro-Oncology Institute of Central South University, Changsha, Hunan, 410011, China. ^[1] Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. ^[2] Cancer center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. ^[3] Department of Urology, The Third Hospital of Changsha, Changsha, Hunan, 410011, China. ^[4] Department of Urology, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, China. ^[5]

关键词 BET inhibitors CBX3 CDK4/6 inhibitors CRPC PLK1